Saturday 17 October 2026
Export STLN’s income statement to Excel — free account
Starling Oncology, Inc.
STLN Healthcare Medical Care Facilities
Starling Oncology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $502.7 million, up 27.8% from fiscal 2024. In the quarter to June 2026, revenue grew 34.6%, EPS grew 46.7%, free cash flow grew 196.7% and total debt rose 6.46%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
6.43
0.48
−6.95%
Follow STLN
| Dec '17 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | 3 | 2 | 3 | 4 |
P/E ratio |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
— | — | 11.54 | 4.45 | 0.58 | 0.57 | (0.08) | 1.42 |
P/S ratio |
— | — | 0.00 | 3.18 | 0.46 | 0.52 | 0.06 | 0.65 |
P/FCF ratio |
— | — | 1,256.84 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
— | — | (2.54) | 2.58 | 0.57 | (0.95) | (4.01) | (5.27) |
Beneish M-Score |
— | — | — | (1.89) | (0.91) | (3.63) | (3.24) | (3.39) |
P/Operating CF |
— | — | 632.84 | (27.67) | (8.37) | (43.57) | 5.56 | 101.73 |
P/B ratio |
— | — | 22.72 | 6.20 | 0.95 | 2.97 | 6.48 | 0.00 |
Price to Tangible BV |
— | — | 0.00 | 10.89 | 1.40 | 5.32 | 0.00 | 0.00 |
EV/Sales |
— | — | 0.00 | 2.65 | 0.49 | 0.54 | 0.17 | 0.74 |
EV/EBITDA |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
— | — | 1,268.51 | (16.44) | (2.01) | (4.79) | (2.52) | (15.17) |
EV/FCF |
— | — | 1,268.51 | (15.12) | (1.85) | (4.25) | (2.21) | (13.42) |
Quick Ratio |
— | 0.92 | 0.81 | 4.58 | 3.84 | 3.62 | 1.88 | 1.31 |
Current Ratio |
— | 0.92 | 1.04 | 5.17 | 4.39 | 4.12 | 2.15 | 1.59 |
Net Debt/EBITDA |
— | 10.87 | (1.20) | 2.71 | (0.10) | (0.08) | (0.90) | (2.11) |
Debt/Assets |
0.00% | 0.00% | 18.16% | 0.09% | 30.81% | 41.50% | 53.92% | 47.01% |
Debt/Equity |
— | 0.00 | 0.42 | 0.00 | 0.65 | 1.52 | 25.95 | (4.92) |
Asset Turnover |
— | 0.00 | 5.70 | 1.51 | 1.09 | 1.38 | 2.06 | 2.98 |
Operating CF/Net income |
— | 0.00 | (0.04) | 2.99 | (406.29) | 0.44 | 0.41 | 0.41 |
Capex/Depreciation |
— | — | (0.37) | (0.90) | (0.35) | (0.17) | (0.31) | (0.21) |
Interest Coverage |
— | — | (23.62) | (143.31) | (20.08) | (11.36) | (8.02) | (3.20) |
| — | (0.02%) | (101.85%) | (16.52%) | 0.13% | (92.20%) | (213.36%) | 999.19% | |
| — | (9.20%) | (43.57%) | (8.12%) | 0.07% | (35.28%) | (33.86%) | (35.93%) | |
ROIC |
— | 0.00% | (15.05%) | 0.00% | (39.40%) | (78.92%) | (79.86%) | (80.21%) |
Return on Tangible Assets |
— | 100.00% | (445.20%) | (8.51%) | 0.14% | (69.46%) | (89.70%) | (115.51%) |
Average Days of Receivables |
— | — | 33.59 | 38.20 | 58.45 | 48.31 | 45.17 | 43.07 |
Research and Development Expense of Revenue |
— | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 22.34% | 41.07% | 47.40% | 35.11% | 27.41% | 21.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.51 | 0.22 | 0.15 | 0.12 | 0.13 | 0.11 |
Share Based Compensation of Revenue |
— | — | 0.08% | 12.09% | 10.96% | 5.49% | 2.83% | 0.91% |
Graham Net Nets |
— | — | (0.01) | 0.08 | (0.07) | (0.05) | (2.44) | (0.21) |
Graham Number |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.46 |
Earnings Yield |
— | — | (2.24%) | (1.67%) | (1.20%) | (40.00%) | (229.03%) | (15.73%) |
Free Cash Flow Yield |
— | — | 0.08% | (5.50%) | (57.41%) | (24.10%) | (130.36%) | (8.45%) |
Revenue per Share |
— | 0.00 | 3.17 | 3.07 | 3.47 | 4.40 | 5.24 | 5.44 |
Operating CF per Share |
— | 0.00 | 0.01 | (0.49) | (0.85) | (0.49) | (0.35) | (0.27) |
Capex per Share |
— | 0.00 | (0.02) | (0.05) | (0.08) | (0.06) | (0.05) | (0.03) |
Free Cash Flow per Share |
— | 0.00 | (0.01) | (0.54) | (0.92) | (0.55) | (0.40) | (0.30) |
Cash per Share |
— | 0.01 | 0.10 | 1.74 | 1.01 | 1.12 | 0.66 | 0.36 |
Shareholders Equity per Share |
— | 0.00 | 0.48 | 1.57 | 1.69 | 0.77 | 0.05 | (0.17) |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 0.00 | 0.48 | 1.57 | 1.69 | 0.77 | 0.05 | (0.17) |
Free Cash Flow |
— | — | (0.69) | (35.73) | (67.28) | (40.88) | (30.33) | (27.79) |
Working Capital |
— | 0.00 | 1.11 | 124.26 | 100.70 | 108.71 | 60.20 | 41.79 |
Capital Expenditures |
— | — | (1.19) | (3.05) | (5.53) | (4.57) | (3.79) | (3.20) |
Net Current Asset Value |
— | 0.00 | (7.87) | 54.78 | (8.07) | (8.72) | (56.71) | (67.63) |
EV/EBIT |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
— | — | 0.01 | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 |
Price to Operating Income |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||
Depreciation/Fixed assets |
— | — | 1.54 | 0.81 | 1.85 | 2.42 | 1.02 | 1.43 |
Cash ROIC |
— | 0.00% | (1.49%) | (16.28%) | (24.24%) | (18.03%) | (20.72%) | (29.17%) |
Accounts Receivable Turnover |
— | — | 9.74 | 10.54 | 8.19 | 7.78 | 8.59 | 9.31 |
Accounts Payable Turnover |
— | — | 10.68 | 11.50 | 16.08 | 22.24 | 17.52 | 12.63 |
Inventory Turnover |
— | — | 27.92 | 30.05 | 25.53 | 23.08 | 28.62 | 31.68 |
Average Days of Payables |
— | — | 30.63 | 35.02 | 17.07 | 19.90 | 26.16 | 36.96 |
Days of Inventory on Hand |
— | — | 10.55 | 14.49 | 16.87 | 18.86 | 10.80 | 14.45 |
Average Receivables |
— | — | 19.25 | 19.25 | 30.84 | 41.67 | 45.80 | 54.00 |
Average Payables |
— | — | 14.10 | 14.10 | 12.47 | 11.90 | 19.38 | 33.75 |
Average Inventory |
— | — | 5.40 | 5.40 | 7.85 | 11.47 | 11.86 | 13.46 |
Average Assets |
— | 0.03 | 32.87 | 134.56 | 232.55 | 235.45 | 190.98 | 168.69 |
Average Common Equity |
— | 14.06 | 14.06 | 66.13 | 113.67 | 90.10 | 30.31 | (6.07) |
Columns are period end dates